Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kun Run Reports Strong 2008 Results

publication date: Apr 1, 2009

Kun Run Biotechnology, a company that focuses on peptide-based drugs, reported that 2008 revenues climbed 56% to $11.6 million. Net income nearly tripled from the year earlier, rising to $6 million or 52% of sales on a non-GAAP basis. Earnings per share were 24 cents, fully diluted. The $6 million net income number includes a $2.4 million extraordinary gain from the sale of property, and also reflects a one-time charge for a Make-Good Provision, which reduced earnings by $1.3 million. More details...

Stock Symbol: (OTCBB: KURU)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here